The European Parliament,

–  having regard to the Commission delegated regulation (C(2024)01219),

–  having regard to the Commission’s letter of 13 March 2024 asking Parliament to declare that it will raise no objections to the delegated regulation,

–  having regard to the letter from the Committee on Civil Liberties, Justice and Home Affairs to the Chair of the Conference of Committee Chairs,

–  having regard to Article 290 of the Treaty on the Functioning of the European Union,

–  having regard to Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004(1) on drug precursors, and in particular Articles 15 and 15a(5) thereof,

–  having regard to Council Regulation (EC) No 111/2005 of 22 December 2004(2) laying down rules for the monitoring of trade between the Union and third countries in drug precursors, and in particular Articles 30a and 30b(5) thereof,

–  having regard to Rule 111(6) of its Rules of Procedure,

–  having regard to the recommendation for a decision of the Committee on Civil Liberties, Justice and Home Affairs,

–  having regard to the fact that no objections have been raised within the period laid down in Rule 111(6), third and fourth indents, of its Rules of Procedure, which expired on 23 April 2024,

A.  whereas the EU legislative framework on measures to control access to substances used in the manufacture of illicit drugs must be continuously updated to counter the proliferation of the so-called ‘designer precursors’, which are close chemical relatives of traditional drug precursors created to circumvent existing rules;

B.  whereas the sodium salt of Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) has been identified as a newly developed drug precursor used in the production of MDMA (3,4-methylenedioxymethamphetamine), commonly known as ‘ecstasy’;

C.  whereas seven esters of 2-methyl-3-phenyloxirane-2-carboxylic acid (BMK glycidic acid) and six esters of 3-(1,3-benzodioxol-5-yl)-2-methyl-oxirane-2-carboxylic acid (PMK glycidic acid) have been identified as possible substitutes of BMK glycidic acid and PMK glycidic acid, which are controlled precursors under EU law, in the production of illicit drugs such as MDMA, methamphetamine and amphetamine;

D.  whereas it is necessary to amend the list of scheduled substances included in Annex I to Regulation (EC) No 273/2004 and in the Annex to Regulation (EC) No 111/2005 to subject IMDPAM and the identified esters of BMK glycidic acid and PMK glycidic acid to the harmonised control and monitoring measures provided for by those regulations;

E.  whereas measures to control access to newly scheduled substances under Regulations (EC) No 273/2004 and (EC) No 111/2005 should enter into force as soon as possible to prevent the use of those drug precursors for the production and placing on the market of illicit drugs;

F.  whereas in the EU roadmap to fight drug trafficking and organised crime (COM(2023)0641) the European Commission committed to making every effort, in cooperation with Parliament and Council, to fast-track the adoption procedure of future delegated acts scheduling additional substances under Regulations (EC) No 273/2004 and (EC) No 111/2005;

1.  Declares that it has no objections to the delegated regulation;

2.  Instructs its President to forward this decision to the Council and the Commission.

(1) OJ L 47, 18.2.2004, p. 1. (2) OJ L 22, 26.1.2005, p. 1.